SCHEMBL4978911

SCHEMBL4978911

O=C(C(c1ccccc1)C1CCCCC1)N1CCc2cnc(N3CCN(C4CCC4)CC3)nc2CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 8/20 0.49
PTPN11 Q06124 1/20 0.49
ACHE P22303 2/20 0.45
TSHR P16473 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSP90AB1 P08238 2/20 0.39
CHRM1 P11229 1/20 0.39
HSP90AA1 P07900 1/20 0.39
GAA P10253 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
MAPT P10636 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4974977 0.99 CHRM3 (0.48) CHRM3PTPN11ACHETSHRALDH1A1
SCHEMBL4980323 0.89 PTPN11 (0.45) PTPN11ACHETSHRALDH1A1LMNA
SCHEMBL4979714 0.86 PTPN11 (0.42) PTPN11ACHETSHRALDH1A1LMNA
SCHEMBL4980386 0.86 CHRM1 (0.45) PTPN11ACHETSHRALDH1A1LMNA
SCHEMBL4980278 0.84 PTPN11 (0.41) PTPN11ACHETSHRALDH1A1LMNA
SCHEMBL4976359 0.82 HSP90AB1 (0.52) PTPN11ALDH1A1HSP90AB1
SCHEMBL4978771 0.82 HSP90AA1 (0.46) PTPN11HSP90AB1HSP90AA1MAPTHCRTR1
SCHEMBL4976452 0.81 PTPN11 (0.42) PTPN11ALDH1A1HSP90AB1HSP90AA1MAPT
SCHEMBL4974941 0.81 HCRTR1 (0.48) PTPN11LMNAHTTHSP90AB1HSP90AA1
SCHEMBL4980266 0.81 HCRTR1 (0.48) PTPN11LMNAHTTHSP90AB1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
WO-2007146122-A2 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES HRH3, HRH4, HRH2 CHRM3 320/4885PTPN11 4015/4885ACHE 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.